NCT03862339

Brief Summary

Prospective, Non-randomized, Single-arm Study to assess the accuracy of intracardiac echocardiography (ICE) for characterization of arrhythmogenic substrate in patients with ischaemic cardiomyopathy undergoing ventricular tachycardia (VT) ablation

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2018

Typical duration for all trials

Geographic Reach
2 countries

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 9, 2018

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 25, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 5, 2019

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2021

Completed
Last Updated

October 4, 2023

Status Verified

October 1, 2023

Enrollment Period

2.4 years

First QC Date

February 25, 2019

Last Update Submit

October 3, 2023

Conditions

Keywords

Catheter Ablation

Outcome Measures

Primary Outcomes (1)

  • Areas of abnormal contraction (hypokinesia/akinesia) as determined by ICE imaging

    Area with abnormal contraction as correlated the findings on voltage mapping (low voltage) of the left ventricle in patients with a prior myocardial infarction undergoing VT ablation.

    1 week

Secondary Outcomes (1)

  • Areas of abnormal contraction as determined by ICE imaging

    1 week

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with ischaemic cardiomyopathy undergoing ventricular tachycardia (VT) ablation

You may qualify if:

  • Prior heart attack (myocardial infarction) with evidence from prior non-invasive imaging demonstrating regions of the heart with reduced heart muscle function (myocardial hypokinesia/akinesia/thinning) in the absence of a non-heart attack-related (non-ischaemic) cause
  • Age over 18 years
  • One of the following abnormal heart rhythm (VT) events within last 6 months:
  • ≥3 episodes of VT treated with therapeutic rapid pacing from an implantable cardiac defibrillator (antitachycardia pacing \[ATP\])
  • ≥1 appropriate shocks from an implantable cardiac defibrillator
  • ≥3 episodes of abnormal heart rhythm (VT) within 24 hours
  • Sustained VT below the detection rate of the implantable cardiac defibrillator (documented by ECG/cardiac monitor)
  • Sustained abnormal heart rhythm (VT) in the absence of ICD which is documented by ECG/cardiac monitor
  • Patients in whom ICE imaging is planned for the clinical VT ablation procedure (clinical indication)

You may not qualify if:

  • Patient unable or unwilling to provide informed consent.
  • Acute heart attack (acute coronary syndrome with acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of abnormal heart rhythm (VT) - e.g. electrolyte abnormalities or drug-induced abnormal heart rhythms
  • Ineligible for ablation (known to have protruding clot in the chamber of interest (left ventricular thrombus), or have implanted mechanical aortic and mitral valves)
  • Had recent coronary bypass surgery (\< 3 months) or percutaneous coronary intervention (\<3 months)
  • Pregnant patients (pregnancy test will be performed in patients who are of childbearing age who are not on an effective contraceptive prior to all VT ablation procedures)
  • Had recent coronary bypass surgery (\< 3 months) or percutaneous coronary intervention (\<3 months)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Westmead Hospital

Sydney, New South Wales, Australia

Location

Liverpool Heart and Chest Hospital NHS Trust

Liverpool, L14 3PE, United Kingdom

Location

MeSH Terms

Conditions

Tachycardia, Ventricular

Condition Hierarchy (Ancestors)

TachycardiaArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Saagar Mahida, MD

    Liverpool Heart and Chest Hospital

    PRINCIPAL INVESTIGATOR
  • Sharad Agarwal, MD

    Papworth Hospital NHS Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 25, 2019

First Posted

March 5, 2019

Study Start

November 9, 2018

Primary Completion

April 1, 2021

Study Completion

April 1, 2021

Last Updated

October 4, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations